Abstract:Objective: The primary aim of the study was to evaluate the effectiveness and tolerability of aripiprazole on motor and vocal tics in children and adolescents with Tourette's disorder (TD). The secondary aim was to assess the response of TD-associated behaviors to aripiprazole exposure.Methods: This was an 8-week, open-label trial with flexible dosing strategy of aripiprazole in children and adolescaents with TD. A total of 72 patients, aged 6-18 years, participated in the 8-week trial. The Yale Global Tic Severity Scale (YGTSS), the Clinical Global Impressions-Tics (CGI-Tics), and the Child Behavior Checklist (CBCL) were compared at the baseline, weeks 2 and 4, and end point. The side effects of aripiprazole, electrocardiogram (ECG), and body mass index (BMI) were evaluated.Results: Over the 8-week trial, aripiprazole administration was associated with a significant decrease in total tic severity as measured by the YGTSS (50.3% reduction by week 8). The mean scores of motor tic in the YGTSS were 17.42 +/- 4.83, 12.93 +/- 3.76, 8.39 +/- 3.70, and 6.75 +/- 3.95 at baseline, weeks 2 and 4, and end point. A significant decrease in the scores was observed in week 2 compared to the baseline, and the scores continued to decrease for the remainder of the study period (degrees of freedom [df] 3, F 96.02, p 0.000). The mean phonic tic scores were 12.71 +/- 4.60, 8.53 +/- 3.26, 6.10 +/- 2.50, and 3.63 +/- 2.20 at baseline, weeks 2 and 4, and end point, respectively. A significant change was observed during week 2 compared to the baseline, and this change continued for the rest of the study period (df = 3, F = 95.16, p = 0.000). Significant improvement was also observed according to the CGI- Tics severity. The mean CGI- Tics severity score was 4.77 +/- 1.69 at baseline and decreased to 2.20 +/- 1.39 at end point (t = 10.70, p = 0.000). A significant reduction of behavior symptoms was noticed according to the CBCL and its subscales between baseline and end point. The majority of subjects tolerated aripiprazole well. The extrapyramidal symptoms (EPS) during this study were negligible. In all 21 (29.2%) of the 72 participants complained of nausea and 19 (26.4%) of them reported sedation. There was no significant difference of BMI between the two phases (df = 64, t = -0.94, p = 0.352). There were no significant changes in laboratory results. ECG monitoring revealed no significant impact on cardiac conduction by aripiprazol.Conclusion: In this preminary open- label trial, aripiprazole showed effectiveness in treating tic symptoms without causing significant weight gain or other serious side effects. Aripiprazole could be an option for TD cases that do not respond to conventional therapies. Further controlled, double- blind studies are warranted.

[Mrna Expression of Dopamine Receptor D2 and Dopamine Transporter in Peripheral Blood Lymphocytes Before and after Treatment in Children with Tic Disorder].

Analysis of 12 cases on proton magnetic resonance spectroscopy of tic disorders

DRD4/DAT1 mRNA expression in attention deficit hyperactivity disorder children before and after methylphenidate treatment

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

A Pilot Study on Plasma and Urine Neurotransmitter Levels in Children with Tic Disorders

[Transmission Disequilibrium Test of DRD4 Exon III 48bp Variant Number Tandem Repeat Polymorphism and Tic Disorder].

Catecholamine-related gene expression in blood correlates with tic severity in tourette syndrome.

Effectiveness And Tolerability Of Aripiprazole In Children And Adolescents With Tourette'S Disorder: A Meta-Analysis

Change of Expression of Dopamine Receptor D3 Gene Mrna in Peripheral Blood Lymphocytes in Childhood-First Onset Schizophrenia Before and after Treatment

Association study of DRD4 exonⅢ48 bp variable number of tandem repeats polymorphism and tic disorder

Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Pilot Study in China

Changes of Cytokines in Children With Tic Disorder

Effect of “qufeng Zhidong Recipe” on Expression of DRD1/DRD2 Mrna in Corpus Striatum of Rats with Tic Disorder

Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue

Association Between Elevated Serum Histidine Decarboxylase and Tumor Necrosis Factor-Alpha Levels and High Risk in tic Disorder Children

Candidate transmission disequilibrium analysis for quantitative traits in tourette syndrome in a chinese family trio sample

Micro-RNAs from Plasma-Derived Small Extracellular Vesicles as Potential Biomarkers for Tic Disorders Diagnosis

Cross-sectional Exploration of the Relationship Between Glutamate Abnormalities and Tic Disorder Severity Using Proton Magnetic Resonance Spectroscopy

Randomized, double-blind, placebo-controlled trial of aripiprazole oral solution in children and adolescents with Tourette's disorder

Depicting the composition of gut microbiota in children with tic disorders: an exploratory study

GABA- and acetylcholine-related gene expression in blood correlate with tic severity and microarray evidence for alternative splicing in Tourette syndrome: a pilot study.